Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Weibel, Daniel; Sturkenboom, Miriam; Black, Steven; de Ridder, Maria; Dodd, Caitlin; Bonhoeffer, Jan; Vanrolleghem, Ann; van der Maas, Nicoline; Lammers, Gert Jan; Overeem, Sebastiaan; Gentile, Angela; Giglio, Norberto; Castellano, Vanesa; Kwong, Jeffrey C.; Murray, Brian J.; Cauch-Dudek, Karen; Juhasz, Diana; Campitelli, Michael; Datta, Alexandre N.; Kallweit, Ulf; Huang, Wan-Ting; Huang, Yu-Shu; Hsu, Chung-Yao; Chen, Hsi-Chung; Giner-Soriano, Maria; Morros, Rosa; Gaig, Carles; Tió, Ester; Perez-Vilar, Silvia; Diez-Domingo, Javier; Puertas, Francisco Javier; Svenson, Lawrence W.; Mahmud, Salaheddin M.; Carleton, Bruce; Naus, Monika; Arnheim-Dahlström, Lisen; Pedersen, Lars; DeStefano, Frank; Shimabukuro, Tom T.

doi:10.1016/j.vaccine.2018.08.008

Back to Previous Page

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Published Date:

August 16 2018

Publisher's site:

http://dx.doi.org/10.1016/j.vaccine.2018.08.008

Source:

Vaccine. 36(41):6202-6211

Language:

English

[PDF-620.56 KB]

Details:

Alternative Title:

Vaccine

Personal Author:

Weibel, Daniel ; Sturkenboom, Miriam ; Black, Steven ; de Ridder, Maria ; Dodd, Caitlin ; ... More ▼

Description:

Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. Methods: We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. Results: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. Conclusions: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study.

Subject:

[+]

Pubmed ID:

30122647

Pubmed Central ID:

PMC6404226

Document Type:

Journal Article

Funding:

CC999999/Intramural CDC HHS/United States

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

File Type:

Supporting Files:

	nihms-1006028-f0001.gif	image/gif
	nihms-1006028-f0001.jpg	image/jpeg
	nihms-1006028-f0002.gif	image/gif
	nihms-1006028-f0002.jpg	image/jpeg
	nihms-1006028-f0003.gif	image/gif
	nihms-1006028-f0003.jpg	image/jpeg
	nihms-1006028.nxml	text/xml
	NIHMS1006028-supplement-Suppl.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document

No Related Documents.

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

You May Also Like:

Have Questions?

CDC INFORMATION

CONNECT WITH CDC